-

$undefined

N/A

(N/A)

Bristol-Myers Squibb NEW YORK STOCK EXCHANGE INC.:BMY Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Location: 430 E 29th St Fl 14, New York, 10016-8367, US | Website: www.bms.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

153.7B

Cash

10.86B

Avg Qtr Burn

N/A

Short % of Float

1.32%

Insider Ownership

0.34%

Institutional Own.

80.78%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KRAZATI (Adagrasib) + Cetuximab Details Cancer, Colorectal cancer , Solid tumor/s	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) + chemotherapy Details Cancer, Non-small cell lung carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Reblozyl®(luspatercept-aamt) Details Cancer, Anemia, Blood cancer, Mutant Myelodysplastic Syndromes	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Camzyos®(mavacamten) Details Hypertrophic cardiomyopathies	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zeposia (ozanimod) Details Multiple sclerosis, Ulcerative colitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Breyanzi® (lisocabtagene maraleucel) Details Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Augtyro™ (Repotrectinib) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KRAZATI (Adagrasib) Details Cancer, Lung cancer, Non-small cell lung carcinoma, Solid tumor/s, Colorectal cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) Details Cancer, Melanoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Abecma (idecabtagene vicleucel) Details Cancer, Melanoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eliquis Details Stroke, Atrial fibrillation, Blood clots	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Augtyro™ (Repotrectinib) Details Solid tumor/s, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) + Cisplatin-Based Chemotherapy Details Cancer, Urothelial carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Breyanzi® (lisocabtagene maraleucel) Details Mantle cell lymphoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotyktu (deucravacitinib) Details Psoriasis, Skin disease/disorder	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo Qvantig™ Subcutaneous [(nivolumab + hyaluronidase (rHuPH20)] Details Cancer, Renal cell carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Breyanzi® (lisocabtagene maraleucel) Details Follicular lymphoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COBENFY™ (xanomeline and trospium chloride) Details Mental health, Schizophrenia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OPDIVO (nivolumab) injection Details Gastric cancer, Gastroesophageal adenocarcinomas	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Hepatocellular carcinoma	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milvexian Details Acute coronary syndrome, Stroke, Atrial fibrillation	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMS-986278 [(LPA1) antagonist] Details Lung disease, Idiopathic pulmonary fibrosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KarXT (M1/M4 muscarinic agonist) Details Schizophrenia, Mental health, Alzheimer's disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KarXT (M1/M4 muscarinic agonist) Details Mental health, Schizophrenia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Breyanzi® (lisocabtagene maraleucel) Details B-cell lymphoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Colorectal cancer , Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) + Yervoy (ipilimumab) Copy Details Non-small cell lung carcinoma, Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Non-small cell lung carcinoma, Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotyktu (deucravacitinib) Details Psoriatic arthritis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zeposia (ozanimod) Details Crohns disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Opdivo® (nivolumab) + relatlimab w/ ENHANZE® Details Cancer, Melanoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adagrasib (KRAZATI®) + Cetuximab Details Solid tumor/s, Colorectal cancer , Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KRAZATI (Adagrasib) Details Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adagrasib (KRAZATI®) + Pembrolizumab Details Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
A/I CELMoD (CC-99282) Details Relapsed/ refractory lymphoma, Non-Hodgkin lymphoma, Cancer	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elzovantinib (TPX-0022) (MET inhibitor) Details Solid tumor/s, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MRTX1719 (PRMT5 inhibitor) Details Cancer, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adagrasib (KRAZATI®) + MRTX0902 Details Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MRTX1133 Details Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Lung cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Golcadomide (CELMoD™ Agent) +rituximab Details Blood cancer, Diffuse large B cell lymphoma, Non-Hodgkin lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adagrasib (KRAZATI®) + VS-6766 Details Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Golcadomide (CELMoD™ Agent) Details Blood cancer, Non-Hodgkin lymphoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KarXT (M1/M4 muscarinic agonist) Details Schizophrenia, Mental health	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KAR-2618 Details Mental health, Major depressive disorder	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMS-986393/CC-95266 Details High Refractory Multiple Myeloma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMS-986365 (CC-94676) Details Castration-resistant prostate cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.